BACKGROUND AND PURPOSE: Positron-emission tomography (PET) is a useful tool in oncology. The aim of this study was to assess the metabolic activity of gliomas using (11)C-methionine (MET), [(18)F] fluorodeoxyglucose (FDG), and (11)C-choline (CHO) PET and to explore the correlation between the metabolic activity and histopathologic features. MATERIALS AND METHODS: PET examinations were performed for 95 primary gliomas (37 grade II, 37 grade III, and 21 grade IV). We measured the tumor/normal brain uptake ratio (T/N ratio) on each PET and investigated the correlations among the tracer uptake, tumor grade, tumor type, and tumor proliferation activity. In addition, we compared the ease of visual evaluation for tumor detection. RESULTS: All 3 of the tracers showed positive correlations with astrocytic tumor (AT) grades (II/IV and III/IV). The MET T/N ratio of oligodendroglial tumors (OTs) was significantly higher than that of ATs of the same grade. The CHO T/N ratio showed a significant positive correlation with histopathologic grade in OTs. Tumor grade and type influenced MET uptake only. MET T/N ratios of more than 2.0 were seen in 87% of all of the gliomas. All of the tracers showed significantly positive correlations with Mib-1 labeling index in ATs but not in OTs and oligoastrocytic tumors. CONCLUSION: MET PET appears to be useful in evaluating grade, type, and proliferative activity of ATs. CHO PET may be useful in evaluating the potential malignancy of OTs. In terms of visual evaluation of tumor localization, MET PET is superior to FDG and CHO PET in all of the gliomas, due to its straightforward detection of "hot lesions".
BACKGROUND AND PURPOSE: Positron-emission tomography (PET) is a useful tool in oncology. The aim of this study was to assess the metabolic activity of gliomas using (11)C-methionine (MET), [(18)F] fluorodeoxyglucose (FDG), and (11)C-choline (CHO) PET and to explore the correlation between the metabolic activity and histopathologic features. MATERIALS AND METHODS: PET examinations were performed for 95 primary gliomas (37 grade II, 37 grade III, and 21 grade IV). We measured the tumor/normal brain uptake ratio (T/N ratio) on each PET and investigated the correlations among the tracer uptake, tumor grade, tumor type, and tumor proliferation activity. In addition, we compared the ease of visual evaluation for tumor detection. RESULTS: All 3 of the tracers showed positive correlations with astrocytic tumor (AT) grades (II/IV and III/IV). The MET T/N ratio of oligodendroglial tumors (OTs) was significantly higher than that of ATs of the same grade. The CHO T/N ratio showed a significant positive correlation with histopathologic grade in OTs. Tumor grade and type influenced MET uptake only. MET T/N ratios of more than 2.0 were seen in 87% of all of the gliomas. All of the tracers showed significantly positive correlations with Mib-1 labeling index in ATs but not in OTs and oligoastrocytic tumors. CONCLUSION:MET PET appears to be useful in evaluating grade, type, and proliferative activity of ATs. CHO PET may be useful in evaluating the potential malignancy of OTs. In terms of visual evaluation of tumor localization, MET PET is superior to FDG and CHO PET in all of the gliomas, due to its straightforward detection of "hot lesions".
Authors: T Ogawa; A Inugami; J Hatazawa; I Kanno; M Murakami; N Yasui; K Mineura; K Uemura Journal: AJNR Am J Neuroradiol Date: 1996-02 Impact factor: 3.825
Authors: O De Witte; I Goldberg; D Wikler; S Rorive; P Damhaut; M Monclus; I Salmon; J Brotchi; S Goldman Journal: J Neurosurg Date: 2001-11 Impact factor: 5.115
Authors: M Utriainen; M Komu; V Vuorinen; P Lehikoinen; P Sonninen; T Kurki; T Utriainen; A Roivainen; H Kalimo; H Minn Journal: J Neurooncol Date: 2003-05 Impact factor: 4.130
Authors: Marc Levivier; Nicolas Massager; David Wikler; José Lorenzoni; Salvador Ruiz; Daniel Devriendt; Philippe David; Françoise Desmedt; Stéphane Simon; Paul Van Houtte; Jacques Brotchi; Serge Goldman Journal: J Nucl Med Date: 2004-07 Impact factor: 10.057
Authors: J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis Journal: J Natl Cancer Inst Date: 1998-10-07 Impact factor: 13.506
Authors: G A Alexiou; K S Polyzoidis; S Voulgaris; S Tsiouris; A D Fotopoulos; A P Kyritsis Journal: AJNR Am J Neuroradiol Date: 2008-11 Impact factor: 3.825
Authors: S Bisdas; T Nägele; H-P Schlemmer; A Boss; C D Claussen; B Pichler; U Ernemann Journal: AJNR Am J Neuroradiol Date: 2009-11-26 Impact factor: 3.825
Authors: Sam E Day; Mikko I Kettunen; Murali Krishna Cherukuri; James B Mitchell; Martin J Lizak; H Douglas Morris; Shingo Matsumoto; Alan P Koretsky; Kevin M Brindle Journal: Magn Reson Med Date: 2010-11-16 Impact factor: 4.668
Authors: Bálint Alkonyi; Harry T Chugani; Otto Muzik; Diane C Chugani; Senthil K Sundaram; William J Kupsky; Carlos E Batista; Csaba Juhász Journal: J Neuroimaging Date: 2011-01-11 Impact factor: 2.486
Authors: Csaba Juhász; Otto Muzik; Diane C Chugani; Harry T Chugani; Sandeep Sood; Pulak K Chakraborty; Geoffrey R Barger; Sandeep Mittal Journal: J Neurooncol Date: 2010-07-30 Impact factor: 4.130
Authors: Vaios Hatzoglou; Gary A Ulaner; Zhigang Zhang; Kathryn Beal; Andrei I Holodny; Robert J Young Journal: Clin Imaging Date: 2012-10-12 Impact factor: 1.605